We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 448

NOC Application and Impeachment Action Consolidated
  • Borden Ladner Gervais LLP
  • Canada
  • March 29 2017

Apotex served an NOA alleging non-infringement and invalidity. Shire filed an application for a prohibition order. Apotex then started an action to


Motion to amend protective order for purposes of new litigation refused
  • Borden Ladner Gervais LLP
  • Canada
  • March 29 2017

In this motion, Novartis sought to amend a protective order that was issued on consent in the context of an application proceeding. The amendment


Prohibition Order Upheld, Appeal re Sound Prediction and Sufficiency Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 22 2017

Teva appealed a decision of the Federal Court ("FC") granting Leo a prohibition order in respect of their psoriasis drug (Decision here; our summary


Summary Judgment Motion in S. 8 Case Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 15 2017

In this case, Abbott and Takeda brought a summary judgment motion as against Apotex, to dismiss the s. 8 proceeding in its entirety. As a preliminary


Patents Relating to Snowmobiles Infringed but Invalid for Insufficiency
  • Borden Ladner Gervais LLP
  • Canada
  • March 8 2017

In an action for patent infringement, the Court considered the infringement and validity of four patents, as well as remedies. The Court reviewed the


Judicial Review of Commissioner's Decision Refusing to Amend Priority Date Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

The Federal Court dismissed Bayer's application for judicial review of the Commissioner of Patents' decision refusing Bayer's request to amend the


Decision to not Remove Solicitors as Counsel for the Defendants Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

The Federal Court of Appeal upheld a decision of the Federal Court dismissing an appeal from the Prothonotary's order wherein he refused to remove


Federal Court Orders Additional Amount of $100,000.00 as Security for the Defendant's Costs
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

Following TearLab's unsuccessful motions for interim and interlocutory injunctions, the Federal Court ordered that TearLab deposit an additional


Decision of Minister of Health Rejecting ANDS Upheld
  • Borden Ladner Gervais LLP
  • Canada
  • February 22 2017

Apotex sought judicial review of a decision of the Minister of Health that had the effect of rejecting its Abbreviated New Drug Submission (ANDS) for


Costs Award of $6.5 million for Plaintiffs' Costs Following Successful Infringement Action Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • February 22 2017

The Court of Appeal dismissed Nova's appeal from the Federal Court's decision awarding the Respondents $6.5 million for costs consequent to their